Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment.
Fatma Meric YilmazMurat AlbayrakPınar TığlıoğluMesut TığlıoğluBuğra SağlamMerih Reis ArasSenem MaralHacer Berna Afacan ÖztürkPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Imatinib is an oral signal inhibitor that targets tyrosine kinase for BCR/ABL, platelet-derived growth factor, stem cell factor, and c-kit (CD117). The conjunctiva and sclera have a large amount of c-kit positive mast cells which are inhibited by imatinib. The inhibition of c-kit positive mast cells by imatinib may be responsible for further exposure of the conjunctival mucosa to injuries.